Docebenone (AA 861) (Synonyms: A-61589, Docebenone) |
Catalog No.GC31940 |
Docebenone (AA 861) (AA 861) is a potent, selective and orally active 5-LO (5-lipoxygenase) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 80809-81-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats[3]Pancreatitis is induced in rats by retrograde injection of 0.4 mL/kg body wt of 6% taurocholic acid into the pancreatic duct. The animals are divided into three groups: control group; administered Docebenone in a single dose of 30 mg/kg; and administered Docebenone in a single dose of 60 mg/kg. The following parameters are examined: serum amylase, lipase, trypsin, blood sugar, and survival rate[3]. |
References: [1]. Nam YH, et al. Leukotriene B(4) receptors BLT1 and BLT2 are involved in interleukin-8 production in human neutrophils induced by Trichomonas vaginalis-derived secretory products. Inflamm Res. 2012 Feb;61(2):97-102. |
Docebenone (AA 861) is a potent, selective and orally active 5-LO (5-lipoxygenase) inhibitor.
Treatment of trichomonads with the 5-LO inhibitor Docebenone, significantly inhibits the ability of trichomonads to secrete LTB4 compared to results for trichomonads treated with medium. Docebenone strongly abolishes the stimulatory effect of TvSP on IL-8 production[1]. Docebenone at 10-200 μM increases [Ca2+]i concentration dependently[2].
Docebenone might protect experimental acute necrotizing pancreatitis in rats[3]. Docebenone suppresses the release of SRS-A by 55-97%, dose-dependently in doses of 10-8-10-5 M in monkeys. The antigen-induced SRS-A release from these fragments is dose dependently inhibited by 25-93% of Docebenone, with doses of 10-8-10-5 M[4].
[1]. Nam YH, et al. Leukotriene B(4) receptors BLT1 and BLT2 are involved in interleukin-8 production in human neutrophils induced by Trichomonas vaginalis-derived secretory products. Inflamm Res. 2012 Feb;61(2):97-102. [2]. Huang JK, et al. AA-861-induced Ca(2+) mobilization in Madin Darby canine kidney cells. Toxicol Appl Pharmacol. 1999 Dec 1;161(2):202-8. [3]. Kiriyama M, et al. Protective effect of AA-861 (5-lipoxygenase inhibitor) on experimental acute necrotizing pancreatitis in rats. Int J Pancreatol. 1993 Jun;13(3):201-8. [4]. Yamamura H, et al. Effect of AA-861, a selective 5-lipoxygenase inhibitor, on models of allergy in several species. Jpn J Pharmacol. 1988 Jul;47(3):261-71.
Cas No. | 80809-81-0 | SDF | |
Synonyms | A-61589, Docebenone | ||
Canonical SMILES | O=C1C(CCCCC#CCCCC#CCO)=C(C)C(C(C)=C1C)=O | ||
Formula | C21H26O3 | M.Wt | 326.43 |
Solubility | DMSO: 250 mg/mL (765.86 mM) | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.0634 mL | 15.3172 mL | 30.6344 mL |
5 mM | 0.6127 mL | 3.0634 mL | 6.1269 mL |
10 mM | 0.3063 mL | 1.5317 mL | 3.0634 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 16 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *